Wharton jelly derived mesenchymal stem cells (University of Jordan)

N/A

Report date: 2023/01/12 15:29:07

Base Information

Drug NameWharton jelly derived mesenchymal stem cells (University of Jordan)
Drug Alias NameWJ-MSCs
ClassificationCell and gene therapy > Cell therapy > Source of cells > Wharton's Jelly-derivedCell and gene therapy > Cell therapy > Stem cell therapy > Mesenchymal stem cells therapy
Mechanisms of ActionStem cell replacements
TargetsNot applicable
Therapy Area/IndicationsAutistic DisorderErectile DysfunctionOsteoarthritis, Knee +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryJordanIndonesia
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesThe University Of Jordan
China Registration ClassN/A

Develop Information

Active CompaniesThe University Of JordanPt. Prodia Stem Cell Indonesia
Inactive CompaniesN/A
Active IndicationsAutistic DisorderErectile DysfunctionOsteoarthritis, Knee +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A